Table 2.
MICs of resistant strains to selected drugs, integron size and gene cassette, nucleotide changes in the gyrA gene, ribotype, and PFGE profile
| Strain no. (travel association) | Ribotype | Pulsotype | MIC (μg/ml)b |
Integron size (bp [gene])c | Point mutation at gyrA (amino acid change)d |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AMC | AMP | CHL | STR | SXT | NAL | CIP | Ser-83 (TCC) | Asp-87 (GAC) | ||||
| CBD 1267 (Florida) | R6d | P22 | 8 | >32 | >32 | >64 | >4 | >32 | 0.25 | 750 (dfr) | TTC (Phe) | None |
| CBD 1346 (Pakistan) | R6d | P22 | 2 | >32 | >32 | >64 | >4 | >32 | 0.12 | 750 (dfr) | TTC (Phe) | None |
| CBD 1347a (India) | R6d | P21 | ≤1 | ≤1 | 16 | >64 | >4 | 16 | 0.03 | None | None | None |
| CBD 1348 (Peru) | R6f | P10a | ≤1 | ≤1 | 8 | ≤32 | 0.25 | >32 | 0.25 | None | TTC (Phe) | None |
| CBD 1349 (India) | R6d | P18 | >32 | 16 | >32 | >64 | >4 | 8 | 0.12 | 750 (dfr) | NA | NA |
| CBD 1350a | R6d | P11 | 8 | >32 | >32 | >64 | >4 | 4 | 0.12 | None | None | None |
| CBD 1353 (Bangladesh) | R6d | P3 | ≤1 | ≤1 | 4 | ≤32 | ≤0.12 | >32 | 0.25 | None | TTC (Phe) | None |
| DOH 10341 (India) | R6b | P2 | ≤1 | ≤1 | 4 | ≤32 | ≤0.12 | >32 | 0.25 | None | TAC (Tyr) | None |
| DOH 10355 (India) | R6c | P20 | ≤1 | ≤1 | 4 | ≤32 | ≤0.12 | >32 | 0.25 | None | TAC (Tyr) | None |
| DOH 10511 (India) | R6c | P19 | ≤1 | ≤1 | 4 | ≤32 | ≤0.12 | >32 | 0.25 | None | TAC (Tyr) | None |
| DOH 10621 (India, UAE) | R3 | P15 | ≤1 | ≤1 | 4 | ≤32 | ≤0.12 | >32 | 0.25 | None | TTC (Phe) | None |
| DOH 10676 (India) | R8 | P20 | ≤1 | ≤1 | 4 | ≤32 | ≤0.12 | >32 | 0.25 | None | TAC (Tyr) | None |
| DOH 10766 (Haiti) | R1a | P16 | ≤1 | ≤1 | 4 | ≤32 | ≤0.12 | 2 | 0.12 | NA | NA | NA |
| DOH 10854 (India) | R1a | P20 | ≤1 | ≤1 | 4 | ≤32 | ≤0.12 | >32 | 0.12 | None | None | AAC (Asn) |
| DOH 101093 (India) | R1b | P14 | ≤1 | ≤1 | 4 | ≤32 | ≤0.25 | >32 | 0.25 | None | TTC (Phe) | None |
| DOH 101094 (India) | R10 | P14 | ≤1 | ≤1 | 4 | ≤32 | ≤0.12 | >32 | 0.12 | None | TTC (Phe) | None |
a
NAL-susceptible control for gyrA mutations.
b
AMP, ampicillin; AMC, amoxicillin-clavulanic acid; CHL, chloramphenicol; SXT, trimethoprim/sulfamethoxazole; NAL, nalidixic acid; STR, streptomycin; CIP, ciprofloxacin. Boldface indicates resistance or intermediate resistance.
c
dfr, dihydrofolate reductase VII; none, no integron or mutation detected.
d
NA, not applicable.